Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Fiche du document
- doi: 10.1136/jitc-2020-000604
- issn: 2051-1426
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1136/jitc-2020-000604
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32532839
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2051-1426
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D60E643508386
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
TherapyCiter ce document
J. Haanen et al., « Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. », Serveur académique Lausannois, ID : 10.1136/jitc-2020-000604
Métriques
Partage / Export
Résumé
Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently, medical oncologists and multidisciplinary teams are hesitant to retreat in this scenario, despite the fact that a number of patients may derive clinical benefit from this approach. Balancing such clinical benefit and treatment-related toxicities for each patient is becoming increasingly challenging as more and more patients with cancer are being treated with checkpoint inhibitors. In this manuscript, we provide an extensive overview of the relevant literature on retreatment after toxicity, and suggest prophylactic approaches to minimize the risk of severe irAE following rechallenge with immune checkpoint blockade, since treatment may be lifesaving in a number of occasions.